

AAIC 2023 On-Demand Presentations
Education and Faculty Disclosure Information

Module Title <small>*Some data presented may be preliminary</small>	Presentations and Faculty Disclosure Information
Alzheimer's disease biomarkers in diverse populations	<p>Plasma Alzheimer's Disease Biomarkers and Brain Amyloid in a Multi-Ethnic Aging Cohort-Breton M. Asken, PhD, ATC <i>has nothing to disclose.</i></p> <p>Tau and Amyloid Plasma Biomarker Analysis in Alzheimer's Disease Cohorts from Diverse Genetic Ancestries- Anthony J. Griswold, PhD <i>has nothing to disclose.</i></p> <p>Ethnoracial differences in the prevalence of amyloid abnormality-Willemijn J. Jansen, PhD <i>has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation: Biogen - Contracted Research</i></p> <p>Effects of structural and social determinants of health and comorbidities on ethno-racial differences in ATN plasma biomarkers of Alzheimer's disease: A HABS-HD study- Karin L. Meeker, PhD <i>has nothing to disclose.</i></p> <p>The role of life course socioeconomic status and midlife brain health in Black adults- Indira C Turney, PhD <i>has nothing to disclose.</i></p> <p>Differential A/T/N Networks of Cerebrospinal Fluid and Neuroimaging Biomarkers and their Prediction of Cognition between Self-reported Black/African American and Non-Hispanic White Individuals- Chengjie Xiong, PhD <i>has nothing to disclose.</i></p>
Psychosocial and other experiential factors at micro-levels and meso-levels related to dementia risk from middle into older age	<p>Social relationship factors, cognitive activity engagement and cognitive decline across 25 years in the Maastricht Ageing Study. -Lukas Duffner, MSc. <i>has nothing to disclose.</i></p> <p>Establishing National Social Exposome Alzheimer's Disease and Related Dementias (ADRD) Infrastructure-Amy J. Kind, MD, PhD <i>has nothing to disclose.</i></p> <p>Sense of Purpose in Life Predicts Reduced Risk for and Delayed Onset of Mild Cognitive Impairment: A Multistate Survival Model-Nathan A Lewis <i>has nothing to disclose.</i></p> <p>Patients living alone with dementia: course of health-related quality of life over time and the impact of collaborative care in Germany- Bernhard Michalowsky, PhD <i>has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation: Biogen - Consulting Fees</i></p> <p>Different typologies of neighborhood resources are associated with cognitive function-Ketlyne Sol, PhD <i>has nothing to disclose.</i></p>

	<p>Allostatic load profiles of stress to predict Alzheimer’s disease: an accessible opportunity to identify risk at early stages-Juliana Nery Souza-Talarico, PhD <i>has nothing to disclose.</i></p>
<p>Psychiatric and neuropsychiatric syndromes</p>	<p>Common neurobiological mechanisms underlying anosognosia and neuropsychiatric symptoms across the Alzheimer’s disease spectrum. - Geoffroy Pierre Gagliardi, PhD <i>has nothing to disclose.</i></p> <p>Psychometric evaluation of the German version of the Mild Behavioural Impairment Checklist (MBI-C)-Jessica Grothe, PhD <i>has nothing to disclose.</i></p> <p>Structural brain network degeneration associated with agitation in dementia-Lisanne M Jenkins, PhD <i>has nothing to disclose.</i></p> <p>Elevated Tau burden in Amygdala and Hippocampus amongst older participants with psychosis-Aubrey S. Johnson <i>has nothing to disclose.</i></p> <p>Increased Genetic Risk for ADHD Potentiates Cognitive Impairment and Brain Hypometabolism in Alzheimer’s Disease Patients-Douglas Teixeira Leffa, MD, PhD <i>has nothing to disclose.</i></p> <p>Apathy, empathy and depression in Alzheimer’s disease and frontotemporal dementia: Examining the constructs and white matter correlates-Halle Quang <i>has nothing to disclose.</i></p>
<p>Dementia care in low- and middle-income countries</p>	<p>Packages of care for dementia at the primary care level-Daisy M Acosta, MD <i>has nothing to disclose.</i></p> <p>End-of-life care of dementia in rural and urban settings-Eniola O Cadmus, PhD, MD <i>has nothing to disclose.</i></p> <p>Management of frontotemporal dementia in low-resource settings-Ratnavalli Ellajosyula, MD, DM <i>has nothing to disclose.</i></p> <p>Inclusion of people with dementia in care planning and delivery of services. -Ishtar Govia, PhD, MTS, MA <i>has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:</i> Roche - Consulting Fees, Scottish Brain Sciences - Consulting Fees</p>
<p>Opportunities and challenges to promote equity in the dementia diagnosis and care in the current landscape of advanced (but less accessible) diagnostic tools and treatment options: The GBHI experience</p>	<p>Towards equity in dementia diagnosis: Identifying and addressing critical gaps in cognitive assessment tools by incorporating multicultural perspectives- Rafi Haddad <i>has nothing to disclose.</i></p> <p>How to Bring Global Voices to Sharing of Dementia Risk Evidence?-Lorina Naci, PhD <i>has nothing to disclose.</i></p> <p>Finding Affordable Biomarkers for Early Diagnosis of Alzheimer’s Disease (AD) in Nigeria-Valentine A Ucheagwu, PhD <i>has nothing to disclose.</i></p>

	<p>Opportunities and challenges to promote equity in the dementia diagnosis in the current Ecuadorian landscape: Healthcare access for all? -Maria M. Unaicho Pilalumbo, MD <i>has nothing to disclose.</i></p>
<p>Sex and gender specific risk factors for cognitive decline and neurodegeneration</p>	<p>Pre-menopausal bilateral oophorectomy (PBO) is associated with reduced late-life white matter integrity on diffusion MRI-Michelle M. Mielke, PhD <i>has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation: Biogen - Consulting Fees, LabCorp - Consulting Fees, Lilly - Consulting Fees, Merck - Consulting Fees, Siemens Healthineers - Consulting Fees, Sunbird Bio - Consulting Fees</i></p> <p>Multiple Socioeconomic Risks and Cognitive Impairment among Community-Dwelling Older Men and Women: Evidence from a Population-Based Survey in India-T. Muhammad, PhD <i>has nothing to disclose.</i></p> <p>Does biological sex moderate the association of nature exposure with brain volume? A cross-sectional analysis of the UK Biobank-Matt W Noseworthy, BSc <i>has nothing to disclose.</i></p> <p>Association between sleep difficulties, bodily symptoms, and subjective cognitive decline in urban Black men-Candidus Nwakasi, PhD <i>has nothing to disclose.</i></p> <p>The Effects of Estrogen on the Risk of Developing Dementia using the UK Biobank Data-Hee Kyung Park, MD, PhD <i>has nothing to disclose.</i></p> <p>Sex-dependent effects on the association between air pollution and longitudinal changes in CSF and plasma biomarkers of Alzheimer’s disease-Natalia Vilor-Tejedor, PhD <i>has nothing to disclose.</i></p>
<p>Novel approaches to address caregiver burden and stress</p>	<p>Factors influencing burden in adult-child and spousal caregivers-Kalisha Bonds Johnson, PhD, RN, PMHNP <i>has nothing to disclose.</i></p> <p>Promoting caregiver mastery in Black dementia caregivers-Glenna S Brewster, PhD, RN, FNP-BC <i>has nothing to disclose.</i></p> <p>Caregiver needs: Lessons from the care ecosystem-Katherine Possin <i>has nothing to disclose.</i></p> <p>Caregiving and caregiver burden in dementia home care-Gerhard Nikolaus Ransmayr, MD <i>has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation: Abbvie, Bial, Eisai, Roche, Stada, - Consulting Fees</i></p>
	<p>Exploring dementia care pathways in seven LMICs with the help of case vignettes – identifying opportunities for strengthening pre- and post-diagnostic support-Klara Lorenz-Dant, PhD <i>has nothing to disclose.</i></p> <p>How much would England’s National Health Service have to invest to bring its capacity to deliver an Alzheimer’s treatment to G7 average capacity levels?-Soeren Mattke, MD, DSc <i>has had a personal financial relationship in</i></p>

<p>World Alzheimer Report 2022: Dementia treatment, care and support – are global health systems ready for what's next?</p>	<p><i>the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:</i> AiCure Technologies - Alzpath - Biogen - Consulting Fees, Boston Millennia Partners - Eisai - Consulting Fees, Novartis - Consulting Fees Roche - Consulting Fees, Senscio Systems -</p> <p>Transitioning from dementia-related stigma to a Community Level Dementia Screening Program in Rural Kenya (DEM-SKY)-Christine W. Musyimi, PhD <i>has nothing to disclose.</i></p> <p>From plan to impact: does a national dementia plan make a difference? Comparing post diagnostic care in England and Malaysia.-Louise Robinson, MBBS, MD, FRCGP <i>has nothing to disclose.</i></p> <p>The Availability and Use of Anti-Dementia Drugs: An International Survey-Eugene Yee Hing Tang, MBChB, PhD <i>has nothing to disclose.</i></p> <p>World Alzheimer Report 2022 - How strong are global health systems: Lessons learned and case studies from across the globe. -Wendy S Weidner, MA <i>has nothing to disclose.</i></p>
<p>The role of neuroimaging in the era of anti-amyloid therapies: challenges and opportunities in research and clinical praxis.</p>	<p>The role of Neuroimaging in Patient Selection and Safety Monitoring during Lecanemab Treatment-Liana G. Apostolova, MD, MS <i>has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation: Avid Pharmaceuticals - Contracted Research Biogen - Consulting Fees, Eisai - Consulting Fees Eli Lilly - Consulting Fees, Contracted Research, Genentech - Consulting Fees, General Electric - Consulting Fees, Life Molecular Imaging - Contracted Research, Roche Diagnostics - Consulting Fees, Contracted Research. Cassava Neurosciences - Ownership Interest</i></p> <p>What time window do AD trajectories depart from normal? Estimating age-related trajectories to chart preclinical phase of Alzheimer's disease and select trial-ready cohorts-David M. Cash, PhD <i>has nothing to disclose.</i></p> <p>Effects of biomarker timing on preclinical cognitive trajectories and tau PET accumulation-Karly Alex Cody, BS <i>has nothing to disclose.</i></p> <p>Biofluid phospho-tau with subthreshold tau-PET predicts higher rates of tau accumulation: implications for secondary prevention trials-Colin Groot, PhD <i>has nothing to disclose.</i></p> <p>Spatial gradients of gene expression, amyloid PET and functional connectome for predicting regional rates of tau-PET increase: towards tau-PET outcome ROIs in clinical trials. -Ying Luan, PhD <i>has nothing to disclose.</i></p>
	<p>Ethnic Variation in Modifiable Risk Factors for Dementia-Phazha LK Bothongo, MSc <i>has nothing to disclose.</i></p> <p>New Anti-Hyperglycaemic Medications and the Risk of Dementia: A Nationwide Population-Based Study-Avi Cohen, MSc <i>has nothing to disclose.</i></p>

<p>Modifiable risk factors and multimorbidities in dementia</p>	<p>Proportion of Dementia Cases in the Oldest-old Attributable to 8 Neuropathological Changes: The 90+ Study-María M. M. Corrada, ScM, ScD <i>has nothing to disclose.</i></p> <p>Systolic Blood Pressure Levels and Probable Dementia : Secondary Analysis of a Randomized Clinical Trial-Byron C Jaeger, PhD <i>has nothing to disclose.</i></p> <p>Patterns and trajectories of multimorbidity prior to dementia: a UK Biobank study-Raihaan Patel, PhD <i>has nothing to disclose.</i></p> <p>Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: a population-based cohort study.-Ilse E. M. vom Hofe, MSc <i>has nothing to disclose.</i></p>
<p>Metabolic and systemic diseases: Associations with dementia and cognition</p>	<p>The Brain Kidney Axis Vascular Cross Talk-Aditi Gupta, MD <i>has nothing to disclose.</i></p> <p>Persistent Systemic Inflammation Mediates the non-Hispanic Black vs non-Hispanic White Disparity in Cognitive Function: A Longitudinal Analysis-Cesar Higgins, MD, MPH, MS <i>has nothing to disclose.</i></p> <p>Investigating the impact of treatment timing on urinary tract infections in dementia at the population level-Helen Lai, MRes <i>has nothing to disclose.</i></p> <p>Associations between metabolic syndrome and markers of brain pathologies: the role of sex-differences-Anna Marseglia, PhD <i>has nothing to disclose.</i></p> <p>The mediating effect of HbA1c levels on the relationship between education and cognitive function-Constantin Reinke, MSc <i>has nothing to disclose.</i></p> <p>Association of kidney function with risk of incident dementia: a prospective cohort study of 275,167 UK Biobank participants-XinRui Wu, MD <i>has nothing to disclose.</i></p>